Analysis of gabapentin in equine plasma with measurement uncertainty estimation by liquid chromatography-tandem mass spectrometry

Journal of Analytical Toxicology

Volumn 35, Issue 2, 2011, Pages 75-84

  Liu, Ying ^a   Uboh, Cornelius E ^a,b   Soma, Lawrence R ^a   Li, Xiaoqing ^a   Guan, Fuyu ^a   You, Youwen ^a   Rudy, Jeffrey A ^b   Chen, Jin Wen ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WEST CHESTER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONITRILE; GABAPENTIN;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; HORSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; REVERSED PHASE LIQUID CHROMATOGRAPHY; ROOM TEMPERATURE; TANDEM MASS SPECTROMETRY;

CONGIOPODIDAE; EQUIDAE;

EID: 79954625142     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/anatox/35.2.75     Document Type: Article

References (52)

1. C.P. Taylor, N.S. Gee, T.Z. Su, J.D. Kocsis, D.F.Welty, J.P. Brown, D.J. Dooley, P. Boden, and L. Singh. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 29: 233-249 (1998).
2. Y.P. Maneuf, Z.D. Luo, and K. Lee.α2δ and the mechanism of action of gabapentin in the treatment of pain. Semin. Cell Dev. Biol. 17: 565-570 (2006).
3. I. Gilron. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. Curr. Opin. Anaethesiol. 20: 456-472 (2007).
4. R.L. Terry, S.M. McDonnell, W. van Eps, L.R. Soma, Y. Liu, C.E. Uboh, P.J. Poate, and B. Driessen. Pharmacokinetic profile and behavioral effects of gabapentin in the horse. J. Vet. Pharmacol. Ther. 33(5): 485-494 (2010).
5. A.A. Jensen, J. Mosbacher, S. Elg, K. Lingenhoehl, T. Lohmann, T. N. Johansen, B. Abrahamsen, J.P. Mattsson, A. Lehmann, B. Bettler, and H. Bräuner-Osborne. The anticonvulsant gabapentin (neuronitin) does not act through γ-aminobutyric acid-B receptors. Mol. Pharmacol. 61: 1377-1384 (2002).
6. A.F. Lehner, J. Stewart, A. Dafalla, K.J. Ely, A.L. Connerly, C.N. Jones, H. ElkHoly, K. Thompson, T. Tobin, and L. Dirikolu. Gabapentin in horses: validation of an analytical method for gabapentin quantitation. J. Anal. Toxicol. 31: 555-565 (2007).
7. G.A. Mellick, L.B. Mellicy, and L.B. Mellick. Gabapentin in the management of reflex sympathetic dystrophy. J. Pain Symptom Manage. 10: 265-266 (1995).
8. T. Sist, V. Filadora, M. Miner, and M. Lema. Gabapentin for idiopathic trigeminal neuralgia: report of two cases. Neurology 48: 1467-1468 (1997).
9. M Rowbotham, N. Harden, B. Stacey, P. Bernstein, and L. Magnus-Miller. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. J. Am.Med. Assoc. 280: 1837-1842 (1998).
10. M. Backonja, A. Beydoun, K.R, Edwards, S.L. Schwartz, V. Fonseca, M. Hes, L. LaMoreaux, and E. Garofalo. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. J. Am.Med. Assoc. 280: 1831-1836 (1998).
11. G. Di Trapani, D. Mei, C. Marra, S. Mazza, and A. Capuano. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin. Ter. 151: 145-148 (2000).
12. J.D. Berry and K.L. Petersen. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 65: 444-447 (2005).
13. H. Rosner, L. Rubin, and A. Kestenbaum. Gabapentin adjunctive therapy in neuropathic pain states. Clin. J. Pain 12: 56-58 (1996).
14. M.H. Yoon and T.L. Yaksh. The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat. Anesth. Analg. 89: 434-439 (1999).
15. T. Donovan-Rodriquez, A.H. Dickenson, and C.E. Urch. Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. Anesthesiology 102: 132-140 (2005).
16. J.S. Kroin, A. Buvanendran, E. Cochran, and K.J. Tuman. Characterization of pain and pharmacologic responses in an animal model of lumbar adhesive arachnoiditis. Spine (Phila Pa 1976) 30: 1828-1831 (2005).
17. M.H. Pollack, J. Matthews, and E.L. Scott. Gabapentin as a potential treatment for anxiety disorders. Am. J. Psychiatry 155: 992-993 (1998).
18. P.W. Wang, C. Santosa, M. Schumacher, M.E. Winsberg, C. Strong, and T.A. Ketter. Gabapentin augmentation therapy in bipolar depression. Bipolar Disord. 4: 296-301 (2002).
19. L. Loprinzi, D.L. Barton, J.A. Sloan, K.M. Zahasky, D.A. Smith, S. Pruthi, P.J. Novotny, E.A. Perez, and B.J. Christensen. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin. Proc. 77: 1159-1163 (2002).
20. J.L Megna, M.M. Iqbal, and A. Aneja. Pharmacology and therapeutics of gabapentin in the treatment of psychiatric disorders; present and future perspectives. Curr. Neuropharm. 1: 187-197 (2003).
21. J.J. Chen and D.M. Swope. Essential tremor; diagnosis and treatment. Pharmacotherapy 23: 1105-1122 (2003).
22. J. Gazulla, J.M. Errea, I. Benavente, and C.J. Tordesillas. Treatment of ataxia in corticol cerebellar atrophy with the GABAergic drug gabapentin. A preliminary study. Eur. Neurol. 52: 7-11 (2004).
23. R. Moretti, P. Torre, R.M. Antonello, M. Ukmar, G. Cazzato, and A. Bava. Gabapentin as a drug therapy of intractable hiccup because of vascular lesion: a three-year follow up. Neurologist 10: 102-106 (2004).
24. R. Spoladore, D. Garroni, G. Fragasso, A. Palloshi, S. Amadio, C. Montano, A. Corti, and A. Margonato. Post cardiac surgery diaphragmatic spasm successfully treated with gabapentin. Int. J. Cardiol. 109: 282-283 (2006).
25. C. Hansen, I. Gilron, and M. Hong. The effects of intrathecal gabapentin on spinal morphine tolerance in the rat tail-flick and paw pressure tests. Anesth. Analg. 99: 1180-1184 (2004).
26. G. Pfeffer, G. Chouinard, and H.C. Margolese. Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. Int. Clin. Psychopharmacol. 20: 179-181 (2005).
27. J.K. Cheng and L.C. Chiou. Mechanisms of the Antinociceptive action of gabapentin. J. Pharm. Sci. 100: 471-486 (2006).
28. S. Haskin. Story of the decade: Barbaro captures the heart of a nation. http://cs.bloodhorse.com/blogs/horse-racing-stevehaskin/archive/2009/12/31/story-of-the-decade-barbarocaptures-the-heart-of-a-nation.aspx.
29. H. Hengy and E.U. Kolle. Determination of gabapentin in plasma and urine by high-performance liquid chromatography and precolumn labeling for ultraviolet detection. J. Chromatogr. 341: 473-478 (1985).
30. G.L. Lensmeyer, T. Kempf, B.E. Gidal, and D.A. Wiebe. Optimized method for determination of gabapentin in serum by highperformance liquid chromatography. Ther. Drug Monit. 17: 251-258 (1995).
31. Z. Zhu and L. Neirinck. High-performance liquid chromatographic method for the determination of gabapentin in human plasma. J. Chromatogr. B 779: 307-312 (2002)
32. G. Forrest, G.J. Sills, J.P. Leach, and M.J. Brodie. Determination of gabapentin in plasma by high-performance liquid chromatography. J. Chromatogr. B 681: 421-425 (1996)
33. N.Wad and G. Krämer. Sensitive high-performance liquid chromatographic method with fluorometric detection for the simultaneous determination of gabapentin and vigabatrin in serum and urine. J. Chromatogr. B 705: 154-158 (1998).
34. N. Ratnaraj and P.N. Patsalos. A high-performance liquid chromatography micromethod for the simultaneous determination of vigabatrin and gabapentin in serum. Ther. Drug Monit. 20: 430-434 (1998).
35. Q. Jiang and S. Li. Rapid high-performance liquid chromatographic determination of serum gabapentin. J. Chromatogr. B 727: 119-123 (1999).
36. P.H. Tang, M.V. Miles, T.A. Glauser, and T. DeGrauw. Automated microanalysis of gabapentin in human serum by high-performance liquid chromatography with fluorometric detection. J. Chromatogr. B 727: 125-129 (1999).
37. D.F. Chollet, L. Goumaz, C. Juliano, and G. Anderegg. Fast isocratic high-performance liquid chromatographic assay method for the simultaneous determination of gabapentin and vigabatrin in human serum. J. Chromatogr. B 746: 311-314 (2000).
38. W.D. Hooper, M.C. Kavanagh, and R.G. Dickinson. Determination of gabapentin in plasma and urine by capillary column gas chromatography. J. Chromatogr. 529: 167-174 (1990).
39. C.E.Wolf, J.J. Saady, and A. Poklis. Determination of gabapentin in serum using solid-phase extraction and gas-liquid chromatography. J. Anal. Toxicol. 20: 498-501 (1996).
40. S.Y. Chang and F.Y.Wang. Determination of gabapentin in human plasma by capillary electrophoresis with laser-induced fluorescence detection and acetonitrile stacking technique. J. Chromatogr. B 799: 265-270 (2004).
41. K.C. Carlsson and J.L.E. Reubsaet. Sample preparation and determination of gabapentin in venous and capillary blood using liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 34: 415-423 (2004).
42. D.R. Ifa, M. Falci, M.E. Moraes, F.A. Bezerra, M.O. Moraes, and G. de Nucci. Gabapentin quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. J. Mass Spectrom. 36: 188-194 (2001).
43. N.V. Ramakrishna, K.N. Vishwottam, M. Koteshwara, S. Manoj. M. Santosh. J. Chidambara, B. Sumatha, D.P.Varma. Rapid quantification of gabapentin in human plasma by liquid chromatography/ tandem mass spectrometry. J. Pharm. Biomed. Anal. 40: 360-368 (2006).
44. F.T. Peters, O.H. Drummer, and F. Musshoff. Validation of new methods. Forensic Sci. Int. 165: 216-224 (2007).
45. T.P. Linsinger, M. Führer, W. Kandler, and R. Schuhmacher. Determination of measurement uncertainty for the determination of triazines in groundwater from validation data. Analyst 126: 211-216 (2001)
46. S. Bell. A beginner's guide to uncertainty of measurement. In Measurement Good Practice Guide, No. 11, NPL. 1999.
47. S. Lee, H. Choi, E. Kim. H. Choi, H. Chung, and K.H. Chung. Estimation of the measurement uncertainty by the bottom-up approach for the determination of methamphetamine and amphetamine in urine. J. Anal. Toxicol. 34: 222-228 (2010).
48. U.S. Food and Drug Administration. Guidance for Industry Bioanalytical Method Validation. Available: http://www.fda.gov/ CDER/GUIDANCE/4252fnl.htm
49. T.M. Adams. In A2LA Guide for the Estimation of Measurement Uncertainty in Testing. American Association of Laboratory Accreditation Manual. July 1, 2002.
50. A2LA Type III Policy on Measurement Uncertainty. American Association of Laboratory Accreditation. August 1, 2002.
51. Y. Luo, J.A. Rudy, C.E. Uboh, L.R. Soma, F. Guan, J.M. Enright, and D.S. Tsang. Quantification and confirmation of flunixin in equine plasma by liquid chromatography-quadrupole time-of-flight mass spectrometry. J. Chromatogr. B 801: 173-184 (2004).
52. Y. You, C.E. Uboh, L.R. Soma, F. Guan, X. Li, J.A. Rudy, and J. Chen. Screening, quantification and confirmation of phenylbutazone and oxyphenbutazone in equine plasma by liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 33: 41-50 (2009).